Sector focus: Pharmaceutical companies

Jonathan Bridges

Tim Woodthorpe

Andrew Hickman

Koichi Funabashi

Komal Dhall

Helen Jones

Chris Stirling

This is the first in a series of reports examining the tax landscape affecting a particular business sector. This report on pharmaceutical companies is prepared by KPMG. It examines:

the tax landscape affecting the sector;
particular transfer pricing issues;
an in-house view of the challenges facing the tax director;
the impact of breakthroughs in intercompany accounting;
intellectual property and R&D issues; and
a case study: Astellas Pharma Inc.

The contributions represent the personal views of the respective authors and do not necessarily represent the views of the organisations the individuals represent.

The pharmaceutical industry and tax

Chris Stirling
Global...

If you or your firm subscribes to Taxjournal.com, please click the login box below:

If you do not subscribe but are a registered user, please enter your details in the following boxes:

Subscribe Now...

Alternatively, you can register free of charge to read a limited amount of subscriber content per month.

Once you have registered, you will receive an email directing you back to read this article in full.

Please reach out to customer services at +44 (0) 330 161 1234 or 'customer.services@lexisnexis.co.uk' for further assistance.

This is the first in a series of reports examining the tax landscape affecting a particular business sector. This report on pharmaceutical companies is prepared by KPMG. It examines:

the tax landscape affecting the sector;
particular transfer pricing issues;
an in-house view of the challenges facing the tax director;
the impact of breakthroughs in intercompany accounting;
intellectual property and R&D issues; and
a case study: Astellas Pharma Inc.

The contributions represent the personal views of the respective authors and do not necessarily represent the views of the organisations the individuals represent.